Background: There are many atrial fibrillation (AF) screening devices available.
| BACKGROUND
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. The prevalence of clinically diagnosed AF is approximately 3% in the adult population, 1-3 but increases steeply with age. 1, 4 At least 20% of all strokes are directly attributable to AF. 5 The attributable risk of AF to stroke increases with higher age which is in contrast to other risk factors for stroke. 6 Oral anticoagulant treatment in AF patients leads to a marked decrease in stroke risk. 7 AF can be asymptomatic, and individuals with asymptomatic AF have been suggested to have a higher risk of stroke than those with symptomatic AF. 8, 9 AF screening can facilitate early detection of AF. According to current European Society of Cardiology guidelines, opportunistic screening in populations aged >65 years is recommended, by pulse palpation or electrocardiogram (ECG) rhythm strip. Systematic screening may be considered in individuals aged >75 years or with high risk of stroke. 10 Prolonged screening has been shown to detect six times more AF in an elderly population compared to single-time point ECG. 11 With the advent of new technology, many new devices for AF detection have been developed. The validation of these devices is commonly performed in an optimal in-office setting, in the young population. 12 However, arrhythmia affects mainly elderly and arrhythmia is seldom present at the time of hospital visit. Hence, there is a need to validate and compare methods for AF screening in an ambulatory setting in the intended population. 13 We aim to compare the yield of AF detection, compliance, and patient-based experience in population screening in elderly individuals, by using intermittent ECG recordings vs continuous event recording.
| METHODS

| Study population
This is a substudy of STROKESTOP II, a Swedish mass-screening study for AF in individuals aged 75 and 76 years. The study protocol has been published previously. 14 
| Inclusion
Consecutive participants were included during the last 8 months of the STROKESTOP II study. All participants were free of AF at baseline and had NT-proBNP ≥125 ng/L. All participants received oral and written information about the substudy and provided informed consent.
| Screening procedure
During inclusion in the STROKESTOP II study, all participants filled out a health questionnaire from which baseline medical data were gathered.
In addition to the one-lead ambulatory handheld Zenicor II device used in STROKESTOP II, participants were equipped with a one-lead continuous event recorder, R-test 4 evolution (Novacor, Rueil Malmasion, France), and were instructed to use the recording devices in parallel for 2 weeks. Both devices had buttons for activation if symptomatic arrhythmia occurred. The participants were also asked to fill out a questionnaire with regards to their experience of the two different AF screening devices including information on completion of the 2-week registration (yes/no), problems leading to discontinuation (free text), ease of use (on a graded ordinal scale 1-5), and effect on daily life. They were also asked to fill out a symptom diary during the 2 weeks.
| Intermittent ECG
To identify ECGs with suspected AF, all intermittent recordings were inspected manually in addition to the validated computerized algorithm used by Zenicor. 15 The Zenicor device has been validated with 92% sensitivity and 96% specificity for AF detection compared to a 12-lead ECG. 12 
| Continuous event recording
The R-test 4 evolution device was programmed to store not only AF suspicious activity, but also other significant arrhythmias (Table S1 ).
The R-test 4 has a monitoring capacity of 32 days and can store a total of 60-minute ECG recording. We chose to interpret arrhythmia episodes automatically displayed by the system, as this reflects normal usage of the device. The device automatically displays the 42 most typical episodes of suspected AF and 10 episodes of each other arrhythmia category. In 15% of the participants, all accessible ECGs were analyzed, without additional arrhythmia diagnosed by extending the manual examination. The algorithm of the R-test 4 device has been validated compared to continuous ECG and has 92% sensitivity and 87% specificity for AF detection. 16 
| Diagnostic criteria for AF
The diagnostic criteria for AF used in the study are according to ESC guidelines: absolute irregular rate-to-rate intervals, no discernable, distinct p-waves, and duration of at least 30 seconds. 10 All participants diagnosed with AF were offered cardiologist follow-up.
| Other significant arrhythmias
Participants with other significant bradyarrhythmias such as seconddegree atrioventricular block Mobitz type II, sinoatrial block or sinoatrial arrest for >2 seconds during daytime or >3 seconds at nighttime, or sinus bradycardia with a frequency of less than 30 beats/min were offered cardiologist follow-up. Similar follow-up was offered to participants with multifocal or broad complex tachycardia consisting of eight or more consecutive beats. 
| Statistical methods
| Ethics
The study complies with the Declaration of Helsinki. The protocol was approved by the regional ethics committee (DNR 2015/2079-31/1, 2016/852-32, and 2017/527-32). All participants provided informed consent.
| RESULTS
Of the 3763 participants in STROKESTOP II, 269 (7%) were included in this comparison study between June 2017 and January 2018.
| Newly diagnosed AF per screening method
Continuous event recording detected AF in 6% (n = 15) of the participants and intermittent ECG detected AF in 2% (n = 5) (P = .002). Using parallel monitoring, no new cases of AF were detected using intermittent ECG monitoring only. Using continuous event recording, AF was detected on average day 4 (IQR: 1-8) compared to day 8 (IQR: [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] using intermittent ECG (P = .135). There was a significant difference in AF detection between the two devices already after 3 days of monitoring (P = 0.03; Figure 1 Individuals diagnosed with AF had lower systolic blood pressure compared to those free of AF. AF was more common in patients reporting diabetes, but was less commonly associated with hypertension, vascular disease, and previous stroke/transient ischemic attack (Table 1 ).
| Other significant arrhythmias
In total, other significant arrhythmias were overall more commonly detected using continuous monitoring compared to intermittent recordings ( Table 2 ). 
| Interpretation burden per screening method
| Compliance and patient experience
Intermittent ECG was graded as easier to tolerate compared to continuous ECG by the participants (Figure 3 ). Median number of intermittent ECG recordings were 55 (IQR: 40-70) out of 56 (98% of expected). Median monitoring time for continuous event recorder was 13.1 (IQR: 11.8-13.9) days out of 14 (94% of expected). Compliance for either device was not affected by the presence of palpitations (P = .559 for intermittent ECG and P = .804 for continuous event recording).
| DISCUSSION
In this ambulatory elderly population, continuous event recording detected three times more new cases of AF compared to intermittent ECG. Both methods were well tolerated and, even in this ambulatory setting, ECG quality was good. The device-based algorithms differed in categorization of AF events, leading to a more time-consuming interpretation for the continuous event recording device.
Continuous event recording detected more AF cases during the first 3 days than intermittent ECG did during 2 weeks. Overall, the detection of 6% new AF is significantly higher than the outcomes of previous screening studies using intermittent ECGs (3-4%). 11, 17 From Figure 2 , one can derive that not only the burden of AF is important for the detection, but also the density and duration of AF episodes.
Less AF is discovered with intermittent recordings in patients with shorter intermittent episodes compared to those with single prolonged episodes. There is currently no gold standard for detection of paroxysmal AF; in this study, we have shown that it might be prudent to consider screening using continuous event recording rather than intermittent recordings, particularly in patients at high risk of stroke.
One might speculate that in order to increase the ease of use and reduce the interpretation burden for the investigator, the duration of continuous event recording could be reduced.
An important aspect of AF screening is to diagnose AF in asymptomatic patients. It might be possible that patients who experienced symptoms of palpitations were more keen to participate in our study, which might have had an impact on generalization and compliance. In differences in ease of use between the devices might lead to lower compliance for continuous monitoring.
To our knowledge, there are no prior studies comparing continuous event recording and intermittent ECG, except our smaller pilot study, where the two devices were used in parallel for 2 weeks;
according to our previous results, continuous event recording detected >2.5 times more participants with AF compared to the intermittent ECG. 18 In prior studies, both devices have shown an increased detection of AF compared to 24-to 48-hour Holter monitoring. When intermittent ECG recordings, using the Zenicor device, for 10 seconds twice In our study, intermittent ECG was graded as more user-friendly than continuous event recording, and previous studies have shown similar results. 20 Also, several studies have reported disadvantages with skin irritation caused by long-term use of external electrodes. 21 Although problems with skin irritation and battery depletion were commonly reported for the continuous event recording device in our study, both screening devices were graded as manageable and the compliance was surprisingly high.
There is an ongoing discussion regarding the stroke risk in screening-detected AF, as patients with screening-detected AF may have short and rare AF episodes. In our study, screening-detected AF was treated equally to clinically detected AF as we hypothesized that patients with AF detected during such short monitoring period are likely to have a high AF burden. In a large matched cohort study of stroke risk in incidentally detected ambulatory AF, individuals with incidentally diagnosed AF were found to have twice as high incidence of stroke compared to individuals with no AF. Anticoagulant treatment reduced stroke risk by >60% and mortality by >40% in these individuals with incidentally detected AF. 22 Although unknown, one might hypothesize that the risk identified during this study might be representative of the risks in screening-detected AF. The current ESC guidelines do not recommend taking AF burden or symptoms into account in stroke risk stratification, and opportunistic AF screening has a class IB recommendation. 10 
| Limitations
The participants were all part of the STROKESTOP II study. It is possible that they were healthier than the general population, as participation in screening studies is known to be higher in healthier individuals. 23 Compliance to the screening methods could also be increased in a highly motivated group participating in a screening study compared to the general population. All participants were elderly and most were Caucasians. In addition, only participants from STROKESTOP II with elevated NT-proBNP levels participated in the study. This could influence the external validity of the study.
Participants with high NT-proBNP levels are more likely to have AF, and this could lead to an increased detection, with a detection bias. As the participants are their own control, this will not affect the results of this study.
Both AF screening methods used in the study are one-lead ECGs, making p-wave analysis difficult. This could introduce a misclassification bias by underestimation of true cases. Neither of the screening devices used have 100% sensitivity for AF detection; hence,
we may have underestimated the true AF prevalence.
| CONCLUSION
Continuous event recording detected three times more new cases of AF compared to intermittent ECG when performed simultaneously in an ambulatory setting for 2 weeks. In our elderly population, both methods were well tolerated, although intermittent ECG was graded as more userfriendly. The ECG quality was good for both methods, but device-based algorithms differed in categorization of AF events, leading to a more time-consuming interpretation for the continuous event recording device. 
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